Sign In
Buy VIVO
$5.74
-0.620 (-9.75%)
At Close: Jun 03, 2026
Week 12 MDA Breakout Stocks - March 2021: Short-Term Picks To Give You An Edge
04:13am, Monday, 22'nd Mar 2021
Two new breakout stocks for Week 12 of 2021 with better than 10% short-term upside potential.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVO
09:54pm, Sunday, 21'st Mar 2021
New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such inv
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVO
04:58pm, Thursday, 18'th Mar 2021
NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such investors are
5 Must-Buy Efficient Stocks to Make Your Portfolio Stand Out
07:35am, Wednesday, 17'th Mar 2021
Crocs (CROX), iRobot (IRBT), Sprouts Farmers Market (SFM), Meridian Bioscience (VIVO) & MEDIFAST (MED) are the top five companies boasting solid efficiency levels at present.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVO
09:46pm, Sunday, 14'th Mar 2021
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such inv
Has Meridian Bioscience (VIVO) Outpaced Other Medical Stocks This Year?
12:31pm, Friday, 12'th Mar 2021
Is (VIVO) Outperforming Other Medical Stocks This Year?
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVO
06:00am, Friday, 12'th Mar 2021
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such investors are a
Meridian Bioscience's (VIVO) Shares March Higher, Can It Continue?
09:51am, Thursday, 11'th Mar 2021
As of late, it has definitely been a great time to be an investor in Meridian Bioscience, Inc. (VIVO).
Meridian Launches its New Air-Dryable Mix for Crude Blood Samples
10:00am, Monday, 08'th Mar 2021
CINCINNATI, March 08, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the l
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVO
06:02pm, Sunday, 07'th Mar 2021
New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such inve
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVO
03:00am, Wednesday, 03'rd Mar 2021
NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). Such investors are advis
Here is Why Growth Investors Should Buy Meridian Bioscience (VIVO) Now
01:39pm, Monday, 01'st Mar 2021
Meridian Bioscience (VIVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
5 Stocks With High Net Income Ratio to Scoop Up
09:08am, Thursday, 25'th Feb 2021
Profitability analysis is considered one of the best possible ways to assess the prospects of a company.
Is Meridian Bioscience (VIVO) Outperforming Other Medical Stocks This Year?
12:09pm, Wednesday, 24'th Feb 2021
Is (VIVO) Outperforming Other Medical Stocks This Year?
Meridian Bioscience issues correction: It can't ship its Revogene SARS-CoV-2 test until EUA is granted
01:47pm, Tuesday, 23'rd Feb 2021
Meridian Bioscience Inc. issued a statement Tuesday afternoon, to correct a statement made earlier regarding its SARS-CoV-2 molecular diagnostic test on its Revogene platform. The stock dropped 8.7%,
